Semaglutide can cause vision problems, particularly in people with type 2 diabetes who already have some degree of diabetic eye disease. The FDA-approved labels for both Ozempic and Wegovy include warnings about diabetic retinopathy complications, and more recent data has raised questions about a rare condition affecting the optic nerve. For most people without diabetes or pre-existing eye disease, the risk appears low, but it’s worth understanding what the evidence actually shows.
Diabetic Retinopathy: The Best-Studied Risk
The clearest link between semaglutide and vision problems involves worsening of diabetic retinopathy, the eye damage caused by years of elevated blood sugar. In the SUSTAIN-6 trial, which followed people with type 2 diabetes and high cardiovascular risk, 3% of patients on semaglutide developed retinopathy-related complications compared to 1.8% on placebo. Among those complications, 1% of semaglutide patients experienced bleeding inside the eye (vitreous hemorrhage) versus 0.4% on placebo, and 0.3% developed diabetes-related blindness compared to 0.1% on placebo.
A separate trial in people with type 2 diabetes and a BMI of 27 or higher found diabetic retinopathy in 4% of patients on semaglutide versus 2.7% on placebo. These numbers are included on the Wegovy prescribing label.
The risk is not evenly distributed. People who already had diabetic retinopathy before starting treatment were significantly more likely to see it worsen: 8.2% of semaglutide patients with a history of retinopathy experienced complications, compared to 5.2% on placebo. Among those with no prior retinopathy, the numbers were much smaller: 0.7% versus 0.4%.
Why Lowering Blood Sugar Fast Can Hurt Your Eyes
This sounds counterintuitive: a medication that improves blood sugar control making eye disease worse. But it’s a recognized phenomenon that predates semaglutide. When blood sugar drops rapidly after being elevated for a long time, the tiny blood vessels in the retina can react badly. The retina has essentially adapted to a high-sugar environment, and a sudden shift can trigger swelling, new fragile blood vessel growth, or bleeding.
A post hoc analysis of the SUSTAIN-6 trial linked the worsening to the speed of blood sugar improvement. Patients on semaglutide saw their HbA1c (a measure of average blood sugar over three months) drop by 1.9% to 2.5% within just 16 weeks, much faster than the placebo group. This rapid correction, rather than semaglutide itself damaging the eye directly, appears to be the main driver. The same pattern has been observed with insulin therapy and other treatments that produce fast glycemic improvement.
This is why the risk concentrates in people who have longstanding diabetes, existing retinopathy, or are on insulin. If your diabetes has been poorly controlled for years and you start semaglutide, the sudden improvement is what your eyes may struggle with.
Optic Nerve Damage: A Rarer Concern
A separate and more recently studied concern involves a condition called NAION (non-arteritic anterior ischemic optic neuropathy), where blood flow to the optic nerve is suddenly reduced. This causes painless, rapid vision loss, usually in one eye. A 2024 study published in JAMA Ophthalmology analyzed data from 37.1 million adults with type 2 diabetes across 14 databases and found a modest increase in NAION risk among semaglutide users.
When researchers compared semaglutide to the patient’s own non-exposure periods, the risk was about 32% higher during semaglutide use. However, when they compared semaglutide users to people taking other diabetes medications like sitagliptin or glipizide, the difference largely disappeared. Only one comparison, against a specific diabetes drug called empagliflozin, showed a statistically significant higher risk.
In early 2025, the European Medicines Agency concluded that NAION should be listed as a very rare side effect of semaglutide. The practical takeaway: NAION remains uncommon overall, but if you experience sudden painless vision loss in one eye while on semaglutide, it requires immediate medical attention.
When Vision Problems Are Most Likely to Appear
Eye-related side effects tend to cluster early in treatment. An analysis of real-world adverse event reports found that the majority of ocular complaints, about 65% for injectable semaglutide and 72% for the oral form, occurred within the first month. The median time to onset was 7 days for injections and 3.5 days for tablets. This timing aligns with the period when blood sugar levels are shifting most dramatically as the body adjusts to the medication.
Some of these early reports involve transient blurred vision, which can happen any time blood sugar levels change significantly and often resolves on its own as levels stabilize. This is different from the more serious retinopathy worsening, which involves structural damage to blood vessels in the eye and doesn’t simply clear up.
Who Faces the Highest Risk
Three factors consistently predict whether someone is more likely to develop vision problems on semaglutide:
- Existing diabetic retinopathy. People who already have retinal damage before starting treatment face the highest absolute risk. The jump from 5.2% to 8.2% in the SUSTAIN-6 trial was concentrated in this group.
- Long duration of diabetes. Having type 2 diabetes for more than 10 years is associated with higher risk of new or worsening eye disease on GLP-1 medications. Longer disease duration generally means more cumulative vascular damage.
- Poorly controlled blood sugar at baseline. The bigger the gap between your current HbA1c and where semaglutide brings it, the more abrupt the metabolic shift your retinal blood vessels experience.
People using semaglutide for weight loss who do not have type 2 diabetes face a fundamentally different risk profile. The retinopathy concern is driven by diabetes-related blood vessel changes that don’t apply if you don’t have diabetes. That said, the NAION signal was small enough and new enough that it hasn’t been fully sorted out by patient population.
What the FDA Label Says
The Wegovy prescribing label lists diabetic retinopathy complications under “Warnings and Precautions” and instructs patients with type 2 diabetes to contact their doctor if they notice changes in vision during treatment. The medication guide specifically asks patients to disclose any history of diabetic retinopathy before starting. The label also notes that the effect of long-term blood sugar control with semaglutide on diabetic retinopathy has not been fully studied.
A five-year clinical trial called FOCUS is currently underway to answer that long-term question. It is tracking whether semaglutide causes sustained worsening of diabetic eye disease or whether the early worsening stabilizes over time, as has been seen with other diabetes treatments that initially provoke retinopathy flares. Results are expected in late 2026 or 2027.
Symptoms That Need Prompt Attention
Mild, temporary blurring during the first few weeks of treatment, especially as blood sugar levels shift, is relatively common and typically resolves. The symptoms that warrant a call to your doctor are different in character: sudden loss of vision (partial or complete) in one or both eyes, a noticeable increase in floaters or dark spots, flashes of light, or a shadow or curtain effect across part of your visual field. These can signal vitreous hemorrhage, retinopathy progression, or optic nerve involvement, all of which benefit from early treatment.
If you have type 2 diabetes and are starting semaglutide, getting an eye exam before treatment gives your eye doctor a baseline to compare against. This is especially important if you have any existing retinopathy, have had diabetes for a decade or more, or are starting from a high HbA1c where the expected blood sugar drop will be steep.